Sugi Predict

Sugi Predict / Targets / MDM2

MDM2

E3 ubiquitin-protein ligase Mdm2 · Q00987 · MDM2 on Sugi Atlas →

157,482 patent compounds predicted against MDM2, 95,584 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL119478 SCHEMBL119478 0.59 7/20
SCHEMBL119548 SCHEMBL119548 0.58 7/20
SCHEMBL120638 SCHEMBL120638 0.58 7/20
SCHEMBL119379 SCHEMBL119379 0.57 7/20
SCHEMBL119483 SCHEMBL119483 0.46 7/20
SCHEMBL178559 SCHEMBL178559 0.45 7/20
SCHEMBL178660 SCHEMBL178660 0.45 7/20
SCHEMBL119708 SCHEMBL119708 0.56 6/20
SCHEMBL119709 SCHEMBL119709 0.56 6/20
SCHEMBL117964 SCHEMBL117964 0.55 6/20
SCHEMBL120511 SCHEMBL120511 0.55 6/20
SCHEMBL178744 SCHEMBL178744 0.55 6/20
SCHEMBL178698 SCHEMBL178698 0.55 6/20
SCHEMBL178733 SCHEMBL178733 0.55 6/20
SCHEMBL178772 SCHEMBL178772 0.55 6/20
SCHEMBL119553 SCHEMBL119553 0.54 6/20
SCHEMBL119590 SCHEMBL119590 0.54 6/20
SCHEMBL119468 SCHEMBL119468 0.54 6/20
SCHEMBL119488 SCHEMBL119488 0.53 6/20
SCHEMBL119475 SCHEMBL119475 0.52 6/20

Clinical trials — most relevant to MDM2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer PHASE2RECRUITING
Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma PHASE2COMPLETED
Phase II Prospective Cohort Study of Intravesical Recombinant Human Type 5 Adenovirus Injection for Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: Evaluating Efficacy and Safety PHASE2NOT_YET_RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation PHASE2UNKNOWN
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma PHASE1/PHASE2COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease PHASE2RECRUITING
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML PHASE2COMPLETED
Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia PHASE1COMPLETED
Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) PHASE1COMPLETED
Gene Therapy in Treating Patients With Ovarian Cancer PHASE1COMPLETED
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies PHASE1COMPLETED
WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck PHASE1COMPLETED
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation PHASE1RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) PHASE1COMPLETED
Safety Study of Infusion of SGT-53 to Treat Solid Tumors PHASE1COMPLETED
Establishment of a Prospective Clinical-biological Database nanRECRUITING
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas nanRECRUITING
Molecular Markers in Cancers and Precancers (MOCA) nanWITHDRAWN
Study of Proteins in Head and Neck Cancer Cells nanCOMPLETED
The Development of Human Papillomavirus Type 16 E7-Specific Human Immunologic Assays in Non-HLA2 Type Human Being nanUNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581 nanCOMPLETED
Comparison of the Human Papillomavirus (HPV) Type 16 E7-Specific Immune Response Between a Normal Population and Patients With Cervical Lesions nanUNKNOWN
Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a MDM2 binder may also engage these)

ProteinNameSimilarity
P56951 — 1.000 P56951 →
P56950 — 1.000 P56950 →
P23804 — 1.000 P23804 →
Q7YRZ8 — 1.000 Q7YRZ8 →
P56273 — 1.000 P56273 →
Q60524 — 0.998 Q60524 →
O42354 — 0.993 O42354 →
Q80XJ2 — 0.992 Q80XJ2 →
Q5XIN1 — 0.992 Q5XIN1 →
Q0IIM1 — 0.990 Q0IIM1 →
Q6GNV6 — 0.990 Q6GNV6 →
A0JM80 — 0.990 A0JM80 →
B2RYR0 — 0.990 B2RYR0 →
Q6DFV7 — 0.989 Q6DFV7 →
Q76N89 — 0.989 Q76N89 →
Q9DAU9 — 0.989 Q9DAU9 →
Q9Z2U2 — 0.989 Q9Z2U2 →
Q8K4P8 — 0.988 Q8K4P8 →
Q9JKY3 — 0.988 Q9JKY3 →
Q70EL1 — 0.987 Q70EL1 →
Q9Y6X4 — 0.987 Q9Y6X4 →
Q8BJL1 — 0.987 Q8BJL1 →
Q5H9M0 — 0.987 Q5H9M0 →
Q7ZUW7 — 0.987 Q7ZUW7 →
Q569C3 — 0.987 Q569C3 →
Q92613 — 0.987 Q92613 →
RNF168 E3 ubiquitin-protein ligase RNF168 0.986 landscape →
Q8BUH8 — 0.986 Q8BUH8 →
Q4V9H5 — 0.986 Q4V9H5 →
A8MW92 — 0.986 A8MW92 →